Pair Name	Oridonin, Cetuximab
Disease Info	[ICD-11: 2C23.Z]	Laryngeal cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Expression	FAS	hsa355
	Down-regulation	Phosphorylation	EGFR	hsa1956
	Down-regulation	Expression	ROS1	hsa6098
	Up-regulation	Expression	MAPK8	hsa5599
In Vitro Model	HEp-2	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_1906
	Tu 212	Head and neck squamous cell carcinoma	Homo sapiens (Human)	CVCL_4915
In Vivo Model	Logarithmically growing HEp-2 cells were harvested by trypsinization, and each mouse was given injections of 1×10⁶ cells subcutaneously into the right flank.
Result	Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: Involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway